Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.
Short position
Clarity Pharmaceuticals (ASX:CU6) has 8.94% of its shares on issue reported as short positions as of 5 Oct 2026, or about 33,345,512 shares. Over the past 30 days that figure has risen 0.39 percentage points, and over 90 days it has risen 1.63 percentage points. Its highest recorded short interest was 10.24% in July 2025. CU6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Clarity Pharmaceuticals (CU6) company profile
Profile, insiders and operations
Company
AI-generated research profile of Clarity Pharmaceuticals
CU6 intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links